![](/img/cover-not-exists.png)
Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
A. Llombart, Galán, C. Fuster, E. Buch, V. Carañana, A. Rodriguez-Lescure, C. Vázquez, A. Guerrero, A. Ruiz, V. Guillam-PortaVolume:
4
Year:
2006
Language:
english
DOI:
10.1016/s1359-6349(06)80382-4
File:
PDF, 131 KB
english, 2006